Fig. 5: Study design and therapeutic journey.
a Overview of study design (CT-155-C-002; NCT05486312) and b therapeutic journey of participants engaging with CT-155 beta. 1Participant engagement and adherence with the study app (CT‑155 beta) were measured passively through the app. Engagement was defined as the number of app opens and sessions of 60 s or greater. Adherence was defined as the number of lessons and goals completed. An independent single-arm, multicenter, exploratory study (CT-155-C-002/NCT05486312) was conducted across ten sites in the United States. The study comprised a screening period, an intervention period, and a follow-up period. The intervention period comprised a 3-week orientation phase with an additional 4-week active phase. The orientation phase included experiences to provide intervention orientation, digital working alliance establishment, and build core therapeutic skills necessary for later stages of intervention. Goals were comprised of 4 steps, where each step is allotted a day to complete. Therefore, 1 goal required a minimum of 4 days to complete. Goal-centered tasks were defined as completing an in-app activity or reporting the completion of the activity during the Activity check-in. CAINS-MAP clinical assessment interview for negative symptoms motivation and pleasure scale, CT-155 beta a beta version of CT-155/BI 3972080, DWA digital working alliance, ENS experiential negative symptoms, MAP-SR motivation and pleasure scale—self report, MARS mobile app rating scale, MDPQ mobile device proficiency questionnaire.
